OncoMatch/Clinical Trials/NCT04025450
Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients
Is NCT04025450 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including Chidamide+VRD and VRD for multiple myeloma.
Treatment: Chidamide+VRD · VRD — In the phase I trial, dose escalation of chidamide will be performed at 4 different dosages (15mg, 20mg, 25mg, 30mg) for optimal dosage, in the phase II trial, the safety and efficacy of chidamide+VRD will be compared with that of VRD regimen.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Disease stage
Required: Stage RISS-3 (RISS)
RISS-3
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: chidamide, bortezomib, lenalidomide, dexamethasone (any of the experimental regimen) (chidamide, bortezomib, lenalidomide, dexamethasone)
Exception: pain-relieving radiotherapy is allowed
Having received any of the medicine of the experiment regimen within 30 days prior to enrollment, pain-relieving radiotherapy is allowed
Lab requirements
Blood counts
Neutrophil count≥1.5×10^9/L, platelet count≥50×10^9/L
Kidney function
eGFR≥40ml/min, except in the case of myeloma-related nephropathy
Liver function
ALT/AST level <2.5 times of the maximum of normal range; total bilirubin<1.5 times of normal maximum
Cardiac function
Normal left ventricular ejection rate, NYHA stage 1
ALT/AST level <2.5 times of the maximum of normal range; total bilirubin<1.5 times of normal maximum; Neutrophil count≥1.5×10^9/L, platelet count≥50×10^9/L; eGFR≥40ml/min, except in the case of myeloma-related nephropathy; Normal left ventricular ejaculation rate, NYHA stage 1, pulmonary function GOLD stage 1
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04025450 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage RISS-3 is required.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages